奥替溴安联合美沙拉秦缓释片治疗溃疡性结肠炎临床研究

目的观察奥替溴安联合美沙拉秦缓释片在溃疡性结肠炎治疗中的疗效,副作用及半年复发率。方法随机将溃疡性结肠炎患者分为治疗组36例,给奥替溴安40 mg,3次/d,美沙拉秦缓释片100 mg,3次/d,餐后服。对照组32例,给予美沙拉秦缓释片,3次/d,餐后服用。均治疗4周。治疗4周后复查肝肾功能,免疫球蛋白,血尿便三大常规及肠镜,并继续随访半年。结果治疗组显效率47.2%,总有效率为86.1%,半年复发率16.7%,无明显副作用。对照组显效率为34.3%,总有效率为71.9%,半年复发率34.4%;副反应主要表现白细胞轻度减少2例(6.3%),轻度胃肠道反应8例(25.0%)。结论奥替溴安联合美沙拉秦缓释片能有效治疗溃疡性结肠炎,副作用少,半年复发率低,优于美沙拉秦缓释片。

The clinical research of Otilonium Bromide and Mesalazine extended release tablets on ulcerative colitis

Objective To investigate the clinical efficacy,adverse effects and the half year relapse rate of Otilonium Bromide and Mesalazine extended release tablets on patients of ulcerative colitis. Methods Patients were randomly divided into the treatment group(36 cases) and control group(32 cases).The patients in treatment group were treated by Otilonium Bromide 40mg,three times daily and Mesalazine extended release tablets 100mg,three times daily after meals,while the patients in control group by Mesalazine extended release tablets100mg,three times daily after meals,with a treatment course of 4 weeks for both groups,After 4 weeks,the hepatic function,immunoglobulin,3 kinds of conventional detections and enteroscope were reviewed and followed-up for 6 months. Results The effectual rate in treatment group and control group were 47.2% and 34.3%.Total effective rate in treatment group and control group were 86.1% and 71.9%,while the half year relapse rate were 16.7% and 34.4%,the main side effects were mild leukocytopenia(2 cases,6.3%),mild gastrointestinal reactions(8 cases,25%). Conclusion Otilonium Bromide and Mesalazine extended release tablets have good treatment effect on ulcerative colitis with less adverse effects and lower half year relapse rate,it is better than Mesalazine extended release tablets.